Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
I'm 18 and founded an AI startup. I have to wake up at 3 a.m. to work on it before school, but it's worth every sleepless night. - 2Well known Worldwide Caf\u00e9s to Experience
- 3Collection of 7,000-year-old ostrich eggs discovered under sand dunes in southern Israel
- 4Iranian naval commander Alireza Tangsiri killed in attack, says Israel
- 5The most effective method to Guarantee Simple Availability in Seniors' SUVs
- Get away from the Tedious Drudgery: Go into Business Today!
- German diesel hits new records over Easter weekend
- Manual for Big name Work out schedules
- Warming winters lead to more nitrate pollution in the drinking water near farms
- How Deforestation Is Reshaping Mosquito-Human Contact
- Iran fires one of largest barrages in weeks ahead of Passover
- From candy cane fishing to ornament switcharoo, here are some of the best games you can play with your loved ones this holiday season
- Spain's Easter processions draw more tourists amid Iran war
- It's official: NASA's Artemis 2 moon mission will break humanity's all-time distance record
